What Drives High Costs of Cytoreductive Surgery and HIPEC: Patient, Provider or Tumor?

Volume: 27, Issue: 13, Pages: 4920 - 4928
Published: May 15, 2020
Abstract
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is utilized for peritoneal malignancies and is associated with significant resource use. To address potentially modifiable factors contributing to excessive cost, we sought to determine predictors of high cost of care for patients undergoing CRS/HIPEC.An institutional CRS/HIPEC database was queried for adult patients from 2014 to 2018. Cost was defined as cost for...
Paper Details
Title
What Drives High Costs of Cytoreductive Surgery and HIPEC: Patient, Provider or Tumor?
Published Date
May 15, 2020
Volume
27
Issue
13
Pages
4920 - 4928
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.